CliffBio
small molecule

DUAKLIR PRESSAIR

ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE

Loss of exclusivityMarch 2029latest FDA-listed patent expiry
CompanyAZURITY PHARMACEUTICALS SWITZERLAND GMBH

Drug detail

Brand nameDUAKLIR PRESSAIR
Active ingredientACLIDINIUM BROMIDE; FORMOTEROL FUMARATE
Strength0.4MG/INH;0.012MG/INH
Dosage formPOWDER, METERED
RouteINHALATION
ModalitySmall molecule
FDA approvalMarch 2019
Marketing statusRX

Listed patents

PatentExpiresType
10085974March 2029product
11000517March 2029product

More from AZURITY PHARMACEUTICALS SWITZERLAND GMBH

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

DUAKLIR PRESSAIR patent cliff — loss of exclusivity March 2029 | CliffBio